|
|
|
| home > pmps > autumn 2003 > new orbital welding documentation method improves accuracy for inspections and leads to lower cost per weld |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Orbital tube welding is the recommended method of fabrication for bioprocessing equipment. It has not changed significantly since the 1960s when it was introduced into the aerospace industry. Operators still use the gas tungsten arc welding (GTAW) process and orbit or rotate an electrode around a fixtured weld joint with a predetermined set of weld parameters programmed into the power supply (1). While the orbital welding process itself has remained largely unchanged, advancements in welding system technology have greatly improved weld documentation. For example, today's orbital welding equipment utilises microprocessor technology that provides interface capabilities, enabling data to be transferred to other computers for analysing and customising reports that document quality, cost of welds and other critical information. These types of advancements address increasing requirements for bioprocessing systems.
Weld documentation provides full traceability for all materials and procedures used for construction and maintenance of bioprocessing systems. Such documentation must provide the necessary verification that each weld meets the weld acceptance criteria as defined by the weld specification. In the event of a problem with a system, such as contamination, the documentation provides a means to go back and review each welded connection as part of the effort to track down and find the source.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Phillips-Medisize Enters Agreement with Global Pharmaceutical Company to Acquire Exclusive Ownership of Patents for an Innovative Mini-tablet Dispenser
HUDSON, WI – September 10, 2019 – Phillips-Medisize, a Molex company, announced today an agreement with a Global Pharmaceutical Company, where Phillips-Medisize acquired exclusive ownership of patents supporting an innovative mini-tablet dispenser to accommodate the varied and customized oral dispensing needs of patients.
More info >> |
|
 |
White Papers |
 |
|
Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials
Perceptive Informatics
Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC India
26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India
As
the pharma
industry looks increasingly towards India forhigh quality, low cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer.
At
CPhI & P-MEC India, you will meet the movers and shakers from India’s
pharma machinery, technology and ingredients industries, giving you a
competitive advantage that will help grow your business.
More info >> |
|
|
